Agios Pharmaceuticals Insider Scott Biller Sells 4,500 Shares (AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Scott Biller sold 4,500 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $46.30, for a total value of $208,350.00. Following the transaction, the insider now directly owns 35,000 shares of the company’s stock, valued at approximately $1,620,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Agios Pharmaceuticals (NASDAQ:AGIO) traded down 1.36% on Wednesday, hitting $45.66. The stock had a trading volume of 383,648 shares. Agios Pharmaceuticals has a 52 week low of $15.77 and a 52 week high of $50.37. The stock has a 50-day moving average of $40.14 and a 200-day moving average of $39.93. The company’s market cap is $1.573 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.41) by $0.13. The company had revenue of $8.41 million for the quarter, compared to the consensus estimate of $11.00 million. During the same quarter in the prior year, the company posted ($2.80) earnings per share. The company’s quarterly revenue was up 33.3% on a year-over-year basis. On average, analysts predict that Agios Pharmaceuticals will post $-1.94 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on AGIO shares. Analysts at Citigroup Inc. initiated coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, July 1st. They set a “buy” rating and a $58.00 price target on the stock. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00.
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.